4类药品缺陷通知:Star Pharmaceuticals Ltd,马来酸依那普利/氢氯噻嗪 20 mg/12.5 mg 片,EL(26)A/48
正文 · 中文译文
第4类药品缺陷通知:Star Pharmaceuticals Ltd,马来酸依那普利/氢氯噻嗪20 mg/12.5 mg片剂,EL(26)A/48 Star Pharmaceuticals Limited已通知MHRA(英国药品和健康产品管理局),纸盒正面印制的氢氯噻嗪规格存在排版错误,误将“12.5 mg”印为“12. mg”。 来自: 药品和健康产品管理局 发布日期: 2026年11月12日 信息类型: 药品召回/通知 医学专业: 配药全科诊所和药房 签发日期: 2026年11月12日 目录 DMRC参考编号 上市许可持有人 药品详情 马来酸依那普利/氢氯噻嗪20 mg/12.5 mg片剂 受影响批号 背景 致医疗专业人员的建议 致医疗专业人员向患者提供的建议 附加信息 下载文件 DMRC参考编号 DMRC-41407584 上市许可持有人 Star Pharmaceuticals Ltd 药品详情 马来酸依那普利/氢氯噻嗪20 mg/12.5 mg片剂 PLPI:20636/1651 活性成分:马来酸依那普利/氢氯噻嗪 GTIN:05050114165107 受影响批号 批号 有效期 包装规格 首次分销 Y018198 2027年6月30日 28 2026年9月22日 Y019635 2027年10月31日 28 2025年12月5日 C125483 2028年2月29日 28 2026年3月5日 C135541 2028年11月30日 28 2026年6月8日 背景 Star Pharmaceuticals Limited 已通知 MHRA,纸盒正面印制的氢氯噻嗪规格存在排版错误,误将“12.5 mg”印为“12. mg”。纸盒其他各面、说明书及泡罩铝箔上的规格标示均正确。分销至英国市场的受影响库存量为 1740 盒。 对医疗专业人员的建议: 请医疗专业人员注意本通知中的信息,并应继续配发本产品;片剂质量不受该标签缺陷影响。 与该标签错误相关的风险被认为较低,因为不存在氢氯噻嗪规格标示为 12 mg 的相应马来酸依那普利/氢氯噻嗪复方规格。 建议医疗专业人员在患者咨询时向其保证,该产品即为患者信息说明书中所述的马来酸依那普利 20 mg/氢氯噻嗪 12.5 mg 片剂。 医疗专业人员应向患者提供的建议: 患者应继续按处方服用本药物。这不影响片剂质量。 如有不确定或任何疑问,请向药房或参与您治疗的其他医疗专业人员寻求建议。 出现不良反应或对药物有任何疑问的患者应就医。任何疑似不良反应还应通过 MHRA 黄卡计划报告。 附加信息: 如需了解所有医疗信息咨询及本产品相关信息,请发送电子邮件至 info@drugsrus.co.uk 或致电 020 8423 2111。 本药品通知的接收者应通过转发本通知副本,使其引起相关联系人的注意。请NHS(英国国家医疗服务体系)各地区团队将此通知转发给社区药师和配药全科医生以供参考。 此致 缺陷药品报告中心 10 South Colonnade Canary Wharf London E14 4PU 电话 +44 (0)20 3080 6574 DMRC@mhra.gov.uk 下载文件 第4类药品缺陷通知:Star Pharmaceuticals Ltd,马来酸依那普利/氢氯噻嗪 20 mg/12.5 mg 片剂,EL(26)A/48 目录 探索该主题 警报与召回
正文 · 英文原文
Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48 Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5 mg”. From: Medicines and Healthcare products Regulatory Agency Published: 12 November 2026 Message type: Medicines recall/notification Medical specialty: Dispensing GP practices and Pharmacy Issued: 12 November 2026 Contents DMRC reference number Marketing Authorisation Holder Medicine Details Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets Affected Lot Batch Numbers Background Advice for Healthcare Professionals Advice for Healthcare Professionals to Provide to Patients Additional information Download document DMRC reference number DMRC-41407584 Marketing Authorisation Holder Star Pharmaceuticals Ltd Medicine Details Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets PLPI: 20636/1651 Active ingredient: enalapril maleate / hydrochlorothiazide GTIN: 05050114165107 Affected Lot Batch Numbers Batch No. Expiry Date Pack Size First Distributed Y018198 30/06/2027 28 22/09/2026 Y019635 31/10/2027 28 05/12/2025 C125483 29/02/2028 28 05/03/2026 C135541 30/11/2028 28 08/06/2026 Background Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5 mg”. The strength is correctly presented on all other faces of the carton, the leaflet and the blister foil. The volume of affected stock distributed to the UK market is 1740 packs. Advice for Healthcare Professionals: Healthcare professionals are asked to note the information in this notification and should continue to dispense this product; the quality of the tablets is not impacted by this labelling defect. The risk associated with the labelling error is considered low because no corresponding strengths of the enalapril maleate / hydrochlorothiazide combination where the hydrochlorothiazide strength is expressed as 12 mg exist. Healthcare professionals are advised to reassure patients, if contacted, that the product is enalapril maleate 20 mg / hydrochlorothiazide 12.5 mg tablets as described in the Patient Information Leaflet. Advice for Healthcare Professionals to Provide to Patients: Patients should continue to take this medication as prescribed. This does not affect the quality of the tablets. If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals involved in your treatment. Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme. Additional information: For all medical information enquiries and information on this product, please email info@drugsrus.co.uk or telephone 020 8423 2111. Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 DMRC@mhra.gov.uk Download document Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48 Contents Explore the topic Alerts and recalls